25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LSTA (Lisata) Stock Analysis
Buy, Hold or Sell?

Let's analyze Lisata together

I guess you are interested in Lisata Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Lisata’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Lisata’s Price Targets

I'm going to help you getting a better view of Lisata Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lisata Therapeutics Inc.

I send you an email if I find something interesting about Lisata Therapeutics Inc..

1. Quick Overview

1.1. Quick analysis of Lisata (30 sec.)










1.2. What can you expect buying and holding a share of Lisata? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.92
Expected worth in 1 year
$0.87
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$-2.05
Return On Investment
-94.6%

For what price can you sell your share?

Current Price per Share
$2.17
Expected price per share
$1.87 - $2.3536
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lisata (5 min.)




Live pricePrice per Share (EOD)
$2.17
Intrinsic Value Per Share
$-17.22 - $-2.28
Total Value Per Share
$-14.31 - $0.64

2.2. Growth of Lisata (5 min.)




Is Lisata growing?

Current yearPrevious yearGrowGrow %
How rich?$25.1m$50.2m-$18.8m-59.8%

How much money is Lisata making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$5m$186.5k3.9%
Net Profit Margin-115.3%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Lisata (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lisata?

Welcome investor! Lisata's management wants to use your money to grow the business. In return you get a share of Lisata.

First you should know what it really means to hold a share of Lisata. And how you can make/lose money.

Speculation

The Price per Share of Lisata is $2.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lisata.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lisata, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.92. Based on the TTM, the Book Value Change Per Share is $-0.51 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lisata.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.55-25.3%-0.56-25.9%-0.62-28.5%-0.92-42.5%-0.76-35.1%-0.70-32.4%
Usd Book Value Change Per Share-0.49-22.7%-0.51-23.7%-0.52-24.1%-0.61-28.2%0.052.2%-0.07-3.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.49-22.7%-0.51-23.7%-0.52-24.1%-0.61-28.2%0.052.2%-0.07-3.3%
Usd Price Per Share2.35-2.95-2.92-2.87-2.29-2.76-
Price to Earnings Ratio-1.07--1.31--1.18--1.06--0.78--1.06-
Price-to-Total Gains Ratio-4.78--5.74--6.10--5.07--3.26--5.13-
Price to Book Ratio0.81-0.81-0.50-0.55-0.42-0.24-
Price-to-Total Gains Ratio-4.78--5.74--6.10--5.07--3.26--5.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.17
Number of shares460
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.510.05
Usd Total Gains Per Share-0.510.05
Gains per Quarter (460 shares)-236.0921.69
Gains per Year (460 shares)-944.3886.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-944-95408777
20-1889-18980173164
30-2833-28420260251
40-3778-37860347338
50-4722-47300434425
60-5666-56740520512
70-6611-66180607599
80-7555-75620694686
90-8499-85060781773
100-9444-94500867860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%4.0112.00.03.4%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%6.034.00.015.0%32.080.04.027.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%6.00.0110.05.2%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%6.034.00.015.0%32.080.04.027.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lisata Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.492-0.513+4%-0.522+6%-0.612+25%0.047-1143%-0.072-85%
Book Value Per Share--2.9183.659-20%5.846-50%5.891-50%7.004-58%5.322-45%
Current Ratio--7.5177.783-3%10.588-29%10.960-31%14.722-49%9.650-22%
Debt To Asset Ratio--0.1340.132+1%0.101+32%0.103+30%0.088+52%0.256-48%
Debt To Equity Ratio--0.1530.152+1%0.113+36%0.116+32%0.098+57%0.869-82%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--42168700.00053440172.500-21%71020989.500-41%70656485.402-40%76159919.217-45%56122814.034-25%
Eps---0.549-0.561+2%-0.619+13%-0.922+68%-0.762+39%-0.703+28%
Free Cash Flow Per Share---0.628-0.515-18%-0.548-13%-0.587-6%-0.542-14%-0.616-2%
Free Cash Flow To Equity Per Share---0.631-0.518-18%-0.539-15%-0.586-7%0.062-1111%-0.166-74%
Gross Profit Margin--1.0001.0050%1.0040%1.0030%1.0020%1.068-6%
Intrinsic Value_10Y_max---2.281----------
Intrinsic Value_10Y_min---17.224----------
Intrinsic Value_1Y_max---2.045----------
Intrinsic Value_1Y_min---2.353----------
Intrinsic Value_3Y_max---4.761----------
Intrinsic Value_3Y_min---6.570----------
Intrinsic Value_5Y_max---5.807----------
Intrinsic Value_5Y_min---10.204----------
Market Cap18658094.000-8%20214700.00025366922.500-20%25128239.500-20%24666902.068-18%19672569.217+3%23720228.059-15%
Net Profit Margin----1.1530%-0%-0.3880%-0.2330%-36.2610%
Operating Margin----1.1530%-0%-0.3890%-0.2330%-90.3170%
Operating Ratio---1.498-100%-0%0.504-100%0.302-100%92.122-100%
Pb Ratio0.744-8%0.8050.8090%0.505+60%0.554+45%0.422+91%0.240+236%
Pe Ratio-0.988+8%-1.070-1.312+23%-1.180+10%-1.064-1%-0.781-27%-1.058-1%
Price Per Share2.170-8%2.3502.950-20%2.923-20%2.869-18%2.288+3%2.759-15%
Price To Free Cash Flow Ratio-0.864+8%-0.936-1.581+69%-1.395+49%-1.357+45%-0.976+4%-1.247+33%
Price To Total Gains Ratio-4.415+8%-4.781-5.736+20%-6.101+28%-5.074+6%-3.261-32%-5.134+7%
Quick Ratio--8.4589.759-13%15.142-44%15.526-46%23.231-64%14.806-43%
Return On Assets---0.163-0.136-17%-0.091-44%-0.136-16%-0.102-37%-0.106-35%
Return On Equity---0.186-0.155-17%-0.101-46%-0.151-19%-0.112-40%-0.222+19%
Total Gains Per Share---0.492-0.513+4%-0.522+6%-0.612+25%0.047-1143%-0.072-85%
Usd Book Value--25102000.00031462500.000-20%50263750.000-50%50653333.333-50%60223600.000-58%45761413.775-45%
Usd Book Value Change Per Share---0.492-0.513+4%-0.522+6%-0.612+25%0.047-1143%-0.072-85%
Usd Book Value Per Share--2.9183.659-20%5.846-50%5.891-50%7.004-58%5.322-45%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--42168700.00053440172.500-21%71020989.500-41%70656485.402-40%76159919.217-45%56122814.034-25%
Usd Eps---0.549-0.561+2%-0.619+13%-0.922+68%-0.762+39%-0.703+28%
Usd Free Cash Flow---5402000.000-4432750.000-18%-4715750.000-13%-5050250.000-7%-4660500.000-14%-5296060.300-2%
Usd Free Cash Flow Per Share---0.628-0.515-18%-0.548-13%-0.587-6%-0.542-14%-0.616-2%
Usd Free Cash Flow To Equity Per Share---0.631-0.518-18%-0.539-15%-0.586-7%0.062-1111%-0.166-74%
Usd Market Cap18658094.000-8%20214700.00025366922.500-20%25128239.500-20%24666902.068-18%19672569.217+3%23720228.059-15%
Usd Price Per Share2.170-8%2.3502.950-20%2.923-20%2.869-18%2.288+3%2.759-15%
Usd Profit---4724000.000-4827000.000+2%-5013500.000+6%-7946666.667+68%-6560600.000+39%-6050425.000+28%
Usd Revenue---250000.000-100%-0%10197666.667-100%6118600.000-100%4622375.000-100%
Usd Total Gains Per Share---0.492-0.513+4%-0.522+6%-0.612+25%0.047-1143%-0.072-85%
 EOD+3 -5MRQTTM+11 -23YOY+9 -233Y+11 -235Y+8 -2610Y+10 -24

3.3 Fundamental Score

Let's check the fundamental score of Lisata Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.988
Price to Book Ratio (EOD)Between0-10.744
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.458
Current Ratio (MRQ)Greater than17.517
Debt to Asset Ratio (MRQ)Less than10.134
Debt to Equity Ratio (MRQ)Less than10.153
Return on Equity (MRQ)Greater than0.15-0.186
Return on Assets (MRQ)Greater than0.05-0.163
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Lisata Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.485
Ma 20Greater thanMa 502.461
Ma 50Greater thanMa 1002.595
Ma 100Greater thanMa 2002.521
OpenGreater thanClose2.080
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Lisata Therapeutics Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Fundamental data was last updated by Penke on 2025-08-10 18:02:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Lisata earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Lisata to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lisata Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-115.3%+115.3%
TTM-115.3%YOY--115.3%
TTM-115.3%5Y-23.3%-92.0%
5Y-23.3%10Y-3,626.1%+3,602.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM-115.3%-160.2%+45.0%
YOY--209.8%+209.8%
3Y-38.8%-278.1%+239.3%
5Y-23.3%-362.4%+339.1%
10Y-3,626.1%-517.9%-3,108.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Lisata is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Lisata to theΒ Biotechnology industry mean.
  • -16.3% Return on Assets means thatΒ Lisata generatedΒ $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lisata Therapeutics Inc.:

  • The MRQ is -16.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-13.6%-2.7%
TTM-13.6%YOY-9.1%-4.4%
TTM-13.6%5Y-10.2%-3.3%
5Y-10.2%10Y-10.6%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-12.0%-4.3%
TTM-13.6%-11.9%-1.7%
YOY-9.1%-11.2%+2.1%
3Y-13.6%-11.9%-1.7%
5Y-10.2%-11.6%+1.4%
10Y-10.6%-13.6%+3.0%
4.3.1.3. Return on Equity

Shows how efficient Lisata is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Lisata to theΒ Biotechnology industry mean.
  • -18.6% Return on Equity means Lisata generated $-0.19Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lisata Therapeutics Inc.:

  • The MRQ is -18.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.6%TTM-15.5%-3.1%
TTM-15.5%YOY-10.1%-5.4%
TTM-15.5%5Y-11.2%-4.3%
5Y-11.2%10Y-22.2%+11.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.6%-14.2%-4.4%
TTM-15.5%-14.7%-0.8%
YOY-10.1%-15.0%+4.9%
3Y-15.1%-16.5%+1.4%
5Y-11.2%-17.0%+5.8%
10Y-22.2%-19.2%-3.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lisata Therapeutics Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Lisata is operatingΒ .

  • Measures how much profit Lisata makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Lisata to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lisata Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-115.3%+115.3%
TTM-115.3%YOY--115.3%
TTM-115.3%5Y-23.3%-91.9%
5Y-23.3%10Y-9,031.7%+9,008.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--165.0%+165.0%
TTM-115.3%-237.4%+122.2%
YOY--213.1%+213.1%
3Y-38.9%-267.2%+228.3%
5Y-23.3%-347.4%+324.1%
10Y-9,031.7%-509.4%-8,522.3%
4.3.2.2. Operating Ratio

Measures how efficient Lisata is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lisata Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.498-1.498
TTM1.498YOY-+1.498
TTM1.4985Y0.302+1.195
5Y0.30210Y92.122-91.820
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.960-1.960
TTM1.4982.837-1.340
YOY-3.005-3.005
3Y0.5043.743-3.239
5Y0.3024.738-4.436
10Y92.1226.841+85.281
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lisata Therapeutics Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lisata is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.52Β means the company has $7.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lisata Therapeutics Inc.:

  • The MRQ is 7.517. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.783. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.517TTM7.783-0.266
TTM7.783YOY10.588-2.806
TTM7.7835Y14.722-6.939
5Y14.72210Y9.650+5.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5173.467+4.050
TTM7.7833.689+4.094
YOY10.5884.099+6.489
3Y10.9604.658+6.302
5Y14.7225.739+8.983
10Y9.6506.151+3.499
4.4.3.2. Quick Ratio

Measures if Lisata is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Lisata to theΒ Biotechnology industry mean.
  • A Quick Ratio of 8.46Β means the company can pay off $8.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lisata Therapeutics Inc.:

  • The MRQ is 8.458. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.759. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.458TTM9.759-1.302
TTM9.759YOY15.142-5.382
TTM9.7595Y23.231-13.471
5Y23.23110Y14.806+8.424
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4582.994+5.464
TTM9.7593.326+6.433
YOY15.1423.908+11.234
3Y15.5264.438+11.088
5Y23.2315.809+17.422
10Y14.8066.537+8.269
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lisata Therapeutics Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of LisataΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Lisata to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13Β means that Lisata assets areΒ financed with 13.4% credit (debt) and the remaining percentage (100% - 13.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Lisata Therapeutics Inc.:

  • The MRQ is 0.134. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.132. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.134TTM0.132+0.002
TTM0.132YOY0.101+0.031
TTM0.1325Y0.088+0.044
5Y0.08810Y0.256-0.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1340.340-0.206
TTM0.1320.358-0.226
YOY0.1010.335-0.234
3Y0.1030.343-0.240
5Y0.0880.350-0.262
10Y0.2560.378-0.122
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Lisata is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Lisata to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 15.3% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lisata Therapeutics Inc.:

  • The MRQ is 0.153. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.152. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.153TTM0.152+0.001
TTM0.152YOY0.113+0.039
TTM0.1525Y0.098+0.054
5Y0.09810Y0.869-0.771
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1530.394-0.241
TTM0.1520.440-0.288
YOY0.1130.436-0.323
3Y0.1160.462-0.346
5Y0.0980.468-0.370
10Y0.8690.518+0.351
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Lisata generates.

  • Above 15 is considered overpriced butΒ always compareΒ Lisata to theΒ Biotechnology industry mean.
  • A PE ratio of -1.07 means the investor is paying $-1.07Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lisata Therapeutics Inc.:

  • The EOD is -0.988. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.070. Based on the earnings, the company is expensive. -2
  • The TTM is -1.312. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.988MRQ-1.070+0.082
MRQ-1.070TTM-1.312+0.242
TTM-1.312YOY-1.180-0.131
TTM-1.3125Y-0.781-0.531
5Y-0.78110Y-1.058+0.278
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.988-2.560+1.572
MRQ-1.070-2.297+1.227
TTM-1.312-2.662+1.350
YOY-1.180-3.749+2.569
3Y-1.064-3.773+2.709
5Y-0.781-6.353+5.572
10Y-1.058-7.043+5.985
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lisata Therapeutics Inc.:

  • The EOD is -0.864. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.936. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.581. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.864MRQ-0.936+0.072
MRQ-0.936TTM-1.581+0.645
TTM-1.581YOY-1.395-0.185
TTM-1.5815Y-0.976-0.605
5Y-0.97610Y-1.247+0.271
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.864-3.491+2.627
MRQ-0.936-3.099+2.163
TTM-1.581-3.812+2.231
YOY-1.395-4.274+2.879
3Y-1.357-5.149+3.792
5Y-0.976-8.383+7.407
10Y-1.247-9.373+8.126
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Lisata is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.81 means the investor is paying $0.81Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lisata Therapeutics Inc.:

  • The EOD is 0.744. Based on the equity, the company is cheap. +2
  • The MRQ is 0.805. Based on the equity, the company is cheap. +2
  • The TTM is 0.809. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.744MRQ0.805-0.062
MRQ0.805TTM0.809-0.004
TTM0.809YOY0.505+0.304
TTM0.8095Y0.422+0.387
5Y0.42210Y0.240+0.182
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7442.315-1.571
MRQ0.8052.006-1.201
TTM0.8092.209-1.400
YOY0.5052.431-1.926
3Y0.5542.578-2.024
5Y0.4223.708-3.286
10Y0.2404.430-4.190
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lisata Therapeutics Inc..

4.8.1. Institutions holding Lisata Therapeutics Inc.

Institutions are holding 9.112% of the shares of Lisata Therapeutics Inc..

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc2.956202541826781636.3886
2025-03-31BML Capital Management LLC2.52210.4124216853-67816-23.8228
2025-03-31Renaissance Technologies Corp1.19470.000410272214001.3817
2025-03-31Geode Capital Management, LLC0.70406052946348.2905
2025-03-31BlackRock Inc0.638054857-1156-2.0638
2025-03-31Dimensional Fund Advisors, Inc.0.2933025222-4-0.0159
2025-03-31State Street Corp0.166901434800
2025-03-31Bank of America Corp0.121101041330.0288
2025-03-31Northern Trust Corp0.1194010268102680
2025-03-31HighTower Advisors, LLC0.116801004200
2025-03-31Royal Bank of Canada0.06880591259120
2025-03-31Tower Research Capital LLC0.02570.0002220729215.248
2025-03-31Founders Capital Management Inc0.02330.003200000
2025-03-31Morgan Stanley - Brokerage Accounts0.01710146600
2025-03-31SBI Securities Co Ltd0.00160140-400-74.0741
2025-03-31Banque Transatlantique0.0002020200
2025-03-31JPMorgan Chase & Co0.0002013-2-13.3333
2025-03-31Barclays PLC00400
2025-03-31Cheviot Value Management, Inc.00330
2025-03-31LORING WOLCOTT & COOLIDGE FID ADV LLP00220
Total 8.96940.416771203+20972+2.7%

4.9.2. Funds holding Lisata Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Vanguard Total Stock Mkt Idx Inv2.2743019555300
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr0.66990.00015759600
2025-06-30Fidelity Extended Market Index0.44090.000337911-99-0.2605
2025-06-30Fidelity Series Total Market Index0.10730923000
2025-06-30Northern Trust Extended Eq Market Idx0.08310.0003714200
2025-06-30NT Ext Equity Mkt Idx Fd - L0.08310.0003714200
2025-06-30Spartan Extended Market Index Pool F0.06610.0002568300
2025-06-30Fidelity Total Market Index0.05090437900
2025-07-31Dimensional US Equity Market ETF0.04480.0001385100
2025-06-30DFA US Vector Equity I0.04340.0002373200
2025-05-31DFA US Core Equity Class F0.03680.0002316800
2025-06-30DFA US Targeted Value I0.03530.0001303900
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.03490.0001299800
2025-07-31Dimensional US Small Cap ETF0.03040.0001261400
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.02710.00012328-6-0.2571
2025-06-30DFA US Social Core Equity 2 Portfolio0.02540.0003218500
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.02340.0003201530017.4927
2025-06-30Fidelity Nasdaq Composite Index0.02340201000
2025-07-31Dimensional US Core Equity 2 ETF0.02260194600
2025-06-30Spartan Total Market Index Pool G0.02130183300
Total 4.14440.0027356355+195+0.1%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets28,981
Total Liabilities3,879
Total Stockholder Equity25,356
 As reported
Total Liabilities 3,879
Total Stockholder Equity+ 25,356
Total Assets = 28,981

Assets

Total Assets28,981
Total Current Assets28,617
Long-term Assets364
Total Current Assets
Cash And Cash Equivalents 20,217
Short-term Investments 5,616
Net Receivables 750
Other Current Assets 2,034
Total Current Assets  (as reported)28,617
Total Current Assets  (calculated)28,617
+/-0
Long-term Assets
Property Plant Equipment 74
Intangible Assets 174
Long-term Assets Other 116
Long-term Assets  (as reported)364
Long-term Assets  (calculated)364
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,807
Long-term Liabilities72
Total Stockholder Equity25,356
Total Current Liabilities
Short-term Debt 92
Accounts payable 602
Other Current Liabilities 3,113
Total Current Liabilities  (as reported)3,807
Total Current Liabilities  (calculated)3,807
+/-0
Long-term Liabilities
Long-term Liabilities Other 72
Long-term Liabilities  (as reported)72
Long-term Liabilities  (calculated)72
+/-0
Total Stockholder Equity
Common Stock9
Retained Earnings -552,790
Accumulated Other Comprehensive Income -78
Other Stockholders Equity 578,215
Total Stockholder Equity (as reported)25,356
Total Stockholder Equity (calculated)25,356
+/-0
Other
Capital Stock9
Cash and Short Term Investments 25,833
Common Stock Shares Outstanding 8,602
Liabilities and Stockholders Equity 28,981
Net Debt -20,125
Net Invested Capital 25,356
Net Working Capital 24,810
Property Plant and Equipment Gross 689
Short Long Term Debt Total 92



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-30
> Total Assets 
0
0
0
9,800
10,700
9,600
400
100
100
0
0
0
600
700
400
5,200
6,084
5,764
4,976
4,618
3,134
2,865
2,538
1,836
1,558
1,463
1,495
1,183
1,175
1,188
467
312
119
71
520
99
66
56
64
643
894
1,694
2,039
1,195
1,914
976
4,445
3,775
2,516
2,027
2,288
1,824
1,811
12,425
8,603
106,035
122,003
123,848
116,971
143,025
175,810
170,332
168,215
155,328
167,284
138,026
128,806
54,406
49,897
53,610
57,786
89,816
86,394
133,396
131,339
126,275
118,814
128,625
119,703
57,205
63,185
56,713
57,279
51,833
48,528
72,248
67,555
63,376
56,717
52,093
47,854
44,580
41,288
36,350
31,671
27,153
22,140
37,481
42,019
36,002
114,607
108,614
102,538
97,008
91,463
85,877
78,529
73,034
66,326
62,365
58,089
54,694
48,240
42,571
38,199
35,002
28,981
28,98135,00238,19942,57148,24054,69458,08962,36566,32673,03478,52985,87791,46397,008102,538108,614114,60736,00242,01937,48122,14027,15331,67136,35041,28844,58047,85452,09356,71763,37667,55572,24848,52851,83357,27956,71363,18557,205119,703128,625118,814126,275131,339133,39686,39489,81657,78653,61049,89754,406128,806138,026167,284155,328168,215170,332175,810143,025116,971123,848122,003106,0358,60312,4251,8111,8242,2882,0272,5163,7754,4459761,9141,1952,0391,69489464364566699520711193124671,1881,1751,1831,4951,4631,5581,8362,5382,8653,1344,6184,9765,7646,0845,2004007006000001001004009,60010,7009,800000
   > Total Current Assets 
0
0
0
7,300
7,100
5,900
400
100
100
0
0
0
500
500
300
4,400
5,412
5,124
4,366
3,085
2,150
1,867
1,928
1,574
1,322
1,304
1,354
1,059
1,061
1,084
374
229
54
10
461
49
24
20
35
507
220
1,031
1,400
528
1,248
314
3,748
2,375
1,129
666
919
530
541
10,955
6,389
31,799
41,827
38,760
28,258
46,883
50,438
43,362
45,099
38,610
52,976
52,252
47,886
16,707
12,676
16,449
20,337
50,827
46,556
40,854
41,414
36,282
29,018
47,475
38,482
29,272
35,618
29,254
29,965
24,649
21,934
70,413
65,774
61,110
54,529
51,552
47,253
44,106
39,646
34,818
30,244
25,972
21,206
36,626
41,258
35,331
114,033
108,080
102,107
96,182
90,700
74,947
77,290
71,876
65,298
61,423
57,233
53,924
47,559
41,978
37,692
34,578
28,617
28,61734,57837,69241,97847,55953,92457,23361,42365,29871,87677,29074,94790,70096,182102,107108,080114,03335,33141,25836,62621,20625,97230,24434,81839,64644,10647,25351,55254,52961,11065,77470,41321,93424,64929,96529,25435,61829,27238,48247,47529,01836,28241,41440,85446,55650,82720,33716,44912,67616,70747,88652,25252,97638,61045,09943,36250,43846,88328,25838,76041,82731,7996,38910,9555415309196661,1292,3753,7483141,2485281,4001,0312205073520244946110542293741,0841,0611,0591,3541,3041,3221,5741,9281,8672,1503,0854,3665,1245,4124,4003005005000001001004005,9007,1007,300000
       Cash And Cash Equivalents 
0
0
0
100
0
0
0
0
0
0
0
0
200
400
200
1,600
1,525
1,082
1,145
473
46
75
124
51
42
9
50
19
15
27
33
211
24
2
461
28
5
0
10
489
29
912
1,320
437
1,059
85
3,649
2,304
970
529
794
431
393
10,450
5,849
7,159
11,418
10,959
4,067
15,612
9,412
4,850
11,713
12,745
21,771
2,113
5,391
13,737
9,254
14,722
16,946
46,134
41,360
32,865
32,141
19,174
19,131
36,211
24,043
20,318
25,426
17,700
18,607
14,705
11,998
23,045
15,078
29,163
21,601
22,725
14,374
10,299
14,424
11,754
12,674
14,032
20,745
26,684
21,156
16,512
28,744
12,935
12,772
24,647
12,747
33,348
31,478
32,154
28,155
23,690
32,428
22,593
21,805
28,293
19,509
16,209
20,217
20,21716,20919,50928,29321,80522,59332,42823,69028,15532,15431,47833,34812,74724,64712,77212,93528,74416,51221,15626,68420,74514,03212,67411,75414,42410,29914,37422,72521,60129,16315,07823,04511,99814,70518,60717,70025,42620,31824,04336,21119,13119,17432,14132,86541,36046,13416,94614,7229,25413,7375,3912,11321,77112,74511,7134,8509,41215,6124,06710,95911,4187,1595,84910,4503934317945299702,3043,649851,0594371,3209122948910052846122421133271519509425112475464731,1451,0821,5251,60020040020000000000100000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
300
100
0
2,700
3,752
3,766
2,980
2,376
2,048
1,752
1,742
1,503
1,503
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,146
294
257
1
1
1
1
1
0
0
3
0
0
0
0
0
0
921
665
7,080
0
3,012
5,349
0
0
0
0
0
0
36,325
44,372
25,917
26,984
27,597
31,776
32,754
23,946
21,901
16,487
11,125
0
8,207
19,113
18,061
82,767
93,155
87,377
70,323
75,772
39,643
44,052
37,072
32,940
33,936
21,966
27,942
21,544
9,969
16,347
15,036
5,616
5,61615,03616,3479,96921,54427,94221,96633,93632,94037,07244,05239,64375,77270,32387,37793,15582,76718,06119,1138,207011,12516,48721,90123,94632,75431,77627,59726,98425,91744,37236,3250000005,3493,01207,080665921000000300111112572941,14600000000000000000000000000000001,5031,5031,7421,7522,0482,3762,9803,7663,7522,7000100300000000000000
       Net Receivables 
0
0
0
3,600
2,400
1,600
200
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,250
1,250
1,250
1,000
1,000
1,000
325
0
0
0
0
0
0
0
0
0
0
0
0
9
48
46
45
25
27
31
12
7
12
414
164
5,725
5,496
6,014
4,522
5,871
7,106
7,352
8,945
1,010
10,439
1,257
1,795
1,054
886
702
1,394
1,861
1,888
2,510
2,089
3,111
1,969
1,298
2,300
2,566
2,613
2,892
4,275
139
3,169
336
402
234
144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,100
1
1,000
1,000
1,000
0
900
750
75090001,0001,0001,00011,100000000000000000000001442344023363,1691394,2752,8922,6132,5662,3001,2981,9693,1112,0892,5101,8881,8611,3947028861,0541,7951,25710,4391,0108,9457,3527,1065,8714,5226,0145,4965,7251644141271231272545464890000000000003251,0001,0001,0001,2501,2501,2500000000000000001001002001,6002,4003,600000
       Other Current Assets 
0
0
0
3,600
4,700
4,300
200
0
0
0
0
0
0
0
100
100
134
276
241
236
56
40
63
20
30
46
54
40
46
56
17
18
31
8
0
21
18
20
24
18
191
119
79
82
141
182
53
46
133
106
114
92
136
91
377
5,648
6,193
5,112
4,741
4,375
7,736
6,150
3,858
33,017
2,783
47,722
40,253
803
995
993
1,467
1,562
1,833
2,525
4,376
6,916
7,918
6,954
6,790
6,388
7,579
8,662
7,083
17,434
6,767
10,707
5,923
6,083
5,800
1,229
1,103
1,053
1,276
1,163
1,083
815
461
1,735
989
758
2,522
1,990
1,958
1,212
2,181
1,956
3,520
2,650
4,203
3,797
2,839
3,389
8,420
3,716
1,836
2,433
2,034
2,0342,4331,8363,7168,4203,3892,8393,7974,2032,6503,5201,9562,1811,2121,9581,9902,5227589891,7354618151,0831,1631,2761,0531,1031,2295,8006,0835,92310,7076,76717,4347,0838,6627,5796,3886,7906,9547,9186,9164,3762,5251,8331,5621,46799399580340,25347,7222,78333,0173,8586,1507,7364,3754,7415,1126,1935,6483779113692114106133465318214182791191911824201821083118175646405446302063405623624127613410010000000002004,3004,7003,600000
   > Long-term Assets 
0
0
0
2,500
3,600
3,700
0
0
0
0
0
0
100
200
100
800
673
640
611
1,533
984
998
609
262
236
159
141
124
114
104
93
83
64
61
59
50
42
35
29
135
674
663
639
667
666
662
697
1,400
1,386
1,361
1,368
1,294
1,270
1,470
2,214
74,236
80,176
85,088
88,713
96,142
125,372
126,971
123,116
116,717
114,309
85,774
80,920
37,699
37,221
38,020
37,449
38,989
39,838
92,541
89,925
89,994
89,796
81,150
43,552
27,933
27,567
27,459
27,314
27,184
26,595
1,835
1,782
2,266
2,187
541
601
474
1,642
1,532
1,427
1,181
934
855
761
671
574
534
431
826
763
10,930
1,239
1,158
1,028
942
856
770
681
593
507
424
364
3644245075936817708569421,0281,1581,23910,9307638264315345746717618559341,1811,4271,5321,6424746015412,1872,2661,7821,83526,59527,18427,31427,45927,56727,93343,55281,15089,79689,99489,92592,54139,83838,98937,44938,02037,22137,69980,92085,774114,309116,717123,116126,971125,37296,14288,71385,08880,17674,2362,2141,4701,2701,2941,3681,3611,3861,4006976626666676396636741352935425059616483931041141241411592362626099989841,5336116406738001002001000000003,7003,6002,500000
       Property Plant Equipment 
0
0
0
1,400
1,700
1,800
0
0
0
0
0
0
0
100
100
700
617
579
548
526
486
453
418
74
66
4
0
0
1
2
2
2
3
4
4
3
3
2
2
1
75
69
75
96
97
95
132
164
152
129
118
99
84
139
721
21,299
24,858
30,192
33,208
36,998
48,891
50,286
49,572
49,363
47,328
11,302
11,068
11,153
10,794
10,874
11,331
12,844
13,791
15,639
15,687
15,961
15,852
16,812
17,095
17,065
16,924
17,040
17,124
17,149
16,760
433
364
257
178
98
183
165
148
130
115
100
87
83
720
57
533
492
70
62
55
282
299
296
262
620
204
483
413
344
96
72
74
7472963444134832046202622962992825562704925335772083871001151301481651839817825736443316,76017,14917,12417,04016,92417,06517,09516,81215,85215,96115,68715,63913,79112,84411,33110,87410,79411,15311,06811,30247,32849,36349,57250,28648,89136,99833,20830,19224,85821,2997211398499118129152164132959796756975122334432221004667441845348652654857961770010010000000001,8001,7001,400000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
165
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
581
581
558
558
558
558
558
558
558
558
558
558
558
558
558
29,862
34,426
34,426
35,116
27,002
36,771
37,216
32,587
19,613
19,666
11,118
11,118
11,118
11,118
11,118
11,118
11,118
11,118
26,080
25,209
25,209
25,209
25,209
25,209
7,013
7,013
7,013
7,013
7,013
7,013
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000007,0137,0137,0137,0137,0137,01325,20925,20925,20925,20925,20926,08011,11811,11811,11811,11811,11811,11811,11811,11819,66619,61332,58737,21636,77127,00235,11634,42634,42629,862558558558558558558558558558558558558558581581000000000000000165000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
0
0
0
0
0
0
0
0
0
0
0
0000000000010,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
1,200
1,900
1,900
0
0
0
0
0
0
0
0
0
0
16
16
16
16
16
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
669
669
669
669
634
625
616
607
22,835
15,977
20,152
20,021
29,274
36,565
36,042
35,332
41,805
41,150
14,783
14,632
14,481
14,330
15,038
14,027
13,876
13,724
49,363
47,712
47,560
47,409
37,858
38
2,878
2,735
2,593
2,450
2,308
2,165
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
352
334
317
299
281
263
245
228
210
192
174
1741922102282452632812993173343520000000000000000000002,1652,3082,4502,5932,7352,8783837,85847,40947,56047,71249,36313,72413,87614,02715,03814,33014,48114,63214,78341,15041,80535,33236,04236,56529,27420,02120,15215,97722,83560761662563466966966966900000000000000000000000000161616161600000000001,9001,9001,200000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-860
0
0
0
0
0
0
0
0
37,669
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,389
1,212
0
40
0
0
0
0
23
0
0
0
0
0
0
0000002300004001,2122,3890000000000000000000000037,66900000000-860000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
13,600
15,400
15,600
1,800
1,400
1,400
1,300
1,400
1,600
1,300
1,400
1,600
2,100
980
1,151
1,302
1,487
1,327
1,396
1,441
1,463
1,525
1,677
1,940
2,007
2,137
2,374
1,825
1,814
1,962
1,978
2,193
2,031
2,142
2,351
2,587
2,460
1,912
2,813
653
903
553
812
379
459
401
295
458
961
2,615
8,630
10,417
46,448
56,742
39,057
33,257
56,537
79,543
80,258
67,772
75,195
85,507
86,168
75,100
21,586
20,893
20,618
22,652
27,790
27,327
56,099
69,280
68,202
68,845
62,671
64,706
33,921
50,002
51,076
47,289
47,766
50,504
18,211
14,575
13,186
11,401
8,626
7,044
7,126
6,830
6,728
6,689
6,600
5,156
3,925
4,532
3,760
4,593
3,935
4,125
5,008
3,222
3,740
6,758
6,710
5,623
4,651
5,385
6,800
5,497
4,576
4,763
5,685
3,879
3,8795,6854,7634,5765,4976,8005,3854,6515,6236,7106,7583,7403,2225,0084,1253,9354,5933,7604,5323,9255,1566,6006,6896,7286,8307,1267,0448,62611,40113,18614,57518,21150,50447,76647,28951,07650,00233,92164,70662,67168,84568,20269,28056,09927,32727,79022,65220,61820,89321,58675,10086,16885,50775,19567,77280,25879,54356,53733,25739,05756,74246,44810,4178,6302,6159614582954014593798125539036532,8131,9122,4602,5872,3512,1422,0312,1931,9781,9621,8141,8252,3742,1372,0071,9401,6771,5251,4631,4411,3961,3271,4871,3021,1519802,1001,6001,4001,3001,6001,4001,3001,4001,4001,80015,60015,40013,600000
   > Total Current Liabilities 
0
0
0
6,600
8,700
8,600
700
400
400
300
300
300
500
500
700
900
419
499
503
464
421
433
456
489
582
761
1,049
1,141
1,295
1,553
1,019
1,023
1,198
1,220
1,438
1,288
1,409
1,628
1,872
1,752
1,690
2,663
549
838
520
786
357
444
394
295
458
961
2,615
944
2,680
25,494
31,168
26,678
20,570
32,845
40,949
38,767
31,518
36,445
47,135
48,015
50,435
9,949
9,228
8,385
10,036
9,807
8,786
11,912
11,855
16,245
17,463
16,331
19,740
21,015
18,464
22,357
18,553
19,501
23,212
14,551
11,375
9,313
7,957
5,828
4,892
5,619
5,101
5,712
5,979
5,976
4,620
3,480
4,181
3,506
4,438
3,856
4,072
4,523
2,801
3,357
6,391
6,383
5,286
4,356
5,132
6,590
5,333
4,457
4,691
5,613
3,807
3,8075,6134,6914,4575,3336,5905,1324,3565,2866,3836,3913,3572,8014,5234,0723,8564,4383,5064,1813,4804,6205,9765,9795,7125,1015,6194,8925,8287,9579,31311,37514,55123,21219,50118,55322,35718,46421,01519,74016,33117,46316,24511,85511,9128,7869,80710,0368,3859,2289,94950,43548,01547,13536,44531,51838,76740,94932,84520,57026,67831,16825,4942,6809442,6159614582953944443577865208385492,6631,6901,7521,8721,6281,4091,2881,4381,2201,1981,0231,0191,5531,2951,1411,0497615824894564334214645034994199007005005003003003004004007008,6008,7006,600000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
24
23
23
22
22
22
21
21
22
147
148
208
341
435
410
524
540
660
569
547
628
648
350
767
764
239
222
239
170
99
54
107
73
32
15
1,235
41
147
11,991
14,782
10,902
6,545
12,602
19,266
18,977
11,764
3,782
19,646
3,696
3,629
3,641
1,855
1,273
3,691
594
1,052
1,013
996
1,926
3,305
2,244
3,764
5,364
2,517
6,020
3,065
3,974
4,208
1,029
360
159
92
23
0
0
396
382
368
354
339
349
359
370
381
366
297
229
205
178
203
180
156
160
164
168
172
176
181
137
92
921371811761721681641601561802031782052292973663813703593493393543683823960023921593601,0294,2083,9743,0656,0202,5175,3643,7642,2443,3051,9269961,0131,0525943,6911,2731,8553,6413,6293,69619,6463,78211,76418,97719,26612,6026,54510,90214,78211,991147411,2351532731075499170239222239764767350648628547569660540524410435341208148147222121222222232324230000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135
204
202
145
97
97
108
131
160
259
267
344
427
516
95
88
125
136
227
238
204
214
708
257
455
401
60
372
196
480
151
158
100
138
343
509
743
168
342
8,264
8,907
9,350
7,622
14,287
12,404
9,267
9,896
2,287
19,395
2,171
2,571
2,555
2,191
2,411
3,091
3,355
3,296
5,481
4,400
5,661
2,929
2,266
2,467
4,107
3,985
2,903
3,246
2,227
3,578
1,114
880
1,343
867
506
447
762
553
559
844
1,490
64
592
1,105
1,020
2,315
1,242
768
1,934
697
1,097
974
2,655
1,341
775
1,312
2,421
1,263
728
556
1,284
602
6021,2845567281,2632,4211,3127751,3412,6559741,0976971,9347681,2422,3151,0201,105592641,4908445595537624475068671,3438801,1143,5782,2273,2462,9033,9854,1072,4672,2662,9295,6614,4005,4813,2963,3553,0912,4112,1912,5552,5712,17119,3952,2879,8969,26712,40414,2877,6229,3508,9078,26434216874350934313810015815148019637260401455257708214204238227136125889551642734426725916013110897971452022041350000000000000000
       Other Current Liabilities 
0
0
0
6,600
8,700
8,600
700
400
400
300
300
300
500
500
700
900
261
272
279
295
302
314
326
338
401
480
635
649
660
696
488
525
549
545
551
481
658
786
517
1,146
468
1,497
250
241
85
129
106
229
185
81
78
428
613
613
1,992
2,930
4,177
4,993
4,709
3,004
4,867
9,849
6,201
16,556
7,020
42,148
44,235
2,285
1,683
1,988
3,254
5,858
4,438
5,418
6,459
8,657
11,230
11,821
13,509
11,544
11,962
13,433
6,373
8,203
15,426
5,617
6,060
7,811
6,998
5,299
4,445
4,857
4,152
4,771
4,767
4,132
4,217
2,539
2,717
2,116
1,742
2,248
25,187
31,334
1,899
2,082
5,214
3,548
3,789
3,421
3,656
4,001
3,898
3,553
3,954
4,329
3,113
3,1134,3293,9543,5533,8984,0013,6563,4213,7893,5485,2142,0821,89931,33425,1872,2481,7422,1162,7172,5394,2174,1324,7674,7714,1524,8574,4455,2996,9987,8116,0605,61715,4268,2036,37313,43311,96211,54413,50911,82111,2308,6576,4595,4184,4385,8583,2541,9881,6832,28544,23542,1487,02016,5566,2019,8494,8673,0044,7094,9934,1772,9301,9926136134287881185229106129852412501,4974681,1465177866584815515455495254886966606496354804013383263143022952792722619007005005003003003004004007008,6008,7006,600000
   > Long-term Liabilities 
0
0
0
7,000
6,700
7,000
1,100
1,000
1,000
1,000
1,100
1,300
800
900
900
1,200
561
652
799
1,023
906
963
985
973
943
916
890
866
842
821
806
792
764
757
754
743
733
723
715
708
221
150
105
65
33
26
22
15
8
214
380
533
2,003
7,686
7,737
20,954
25,574
12,378
12,687
23,693
38,594
41,491
36,255
38,750
38,372
38,152
24,664
11,637
11,665
12,233
12,616
17,983
18,540
44,186
57,425
51,957
51,383
46,340
44,966
12,906
31,538
28,719
28,736
28,265
27,292
3,660
3,200
3,873
3,444
2,798
2,152
1,507
1,729
1,016
710
624
536
445
351
254
155
79
53
485
421
383
367
327
337
295
253
210
164
119
72
72
72
72727211916421025329533732736738342148553791552543514455366247101,0161,7291,5072,1522,7983,4443,8733,2003,66027,29228,26528,73628,71931,53812,90644,96646,34051,38351,95757,42544,18618,54017,98312,61612,23311,66511,63724,66438,15238,37238,75036,25541,49138,59423,69312,68712,37825,57420,9547,7377,6862,003533380214815222633651051502217087157237337437547577647928068218428668909169439739859639061,0237996525611,2009009008001,3001,1001,0001,0001,0001,1007,0006,7007,000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
0
0
0
72
0
0
0
0
0
0
00000072000220000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-3,800
-4,700
-6,000
-1,300
-1,200
-1,300
-1,300
-1,400
-1,600
-700
-800
-1,200
3,100
5,104
4,613
3,674
3,131
1,807
1,469
1,097
374
33
-214
-444
-824
-962
-1,186
-1,358
-1,503
-1,844
-1,907
-1,673
-1,932
-2,076
-2,295
-2,524
-1,818
-1,018
-1,119
1,385
292
1,361
164
4,066
3,316
2,114
1,732
1,830
863
-804
3,795
-1,814
24,800
29,934
47,803
45,637
48,660
64,996
62,514
73,561
62,026
63,371
46,352
48,210
33,177
29,425
33,463
35,700
62,542
59,644
78,039
63,003
58,515
50,404
66,382
55,429
23,714
13,662
6,050
10,746
4,884
-791
54,421
53,333
50,508
45,588
43,740
41,082
37,726
34,728
29,889
25,248
20,816
17,243
33,811
37,740
32,496
110,268
104,933
98,667
92,254
88,495
82,391
72,025
66,578
60,957
57,968
52,958
48,148
42,997
38,249
33,690
29,571
25,356
25,35629,57133,69038,24942,99748,14852,95857,96860,95766,57872,02582,39188,49592,25498,667104,933110,26832,49637,74033,81117,24320,81625,24829,88934,72837,72641,08243,74045,58850,50853,33354,421-7914,88410,7466,05013,66223,71455,42966,38250,40458,51563,00378,03959,64462,54235,70033,46329,42533,17748,21046,35263,37162,02673,56162,51464,99648,66045,63747,80329,93424,800-1,8143,795-8048631,8301,7322,1143,3164,0661641,3612921,385-1,119-1,018-1,818-2,524-2,295-2,076-1,932-1,673-1,907-1,844-1,503-1,358-1,186-962-824-444-214333741,0971,4691,8073,1313,6744,6135,1043,100-1,200-800-700-1,600-1,400-1,300-1,300-1,200-1,300-6,000-4,700-3,800000
   Common Stock
0
0
0
200
200
300
300
300
300
300
300
300
0
0
0
0
14
14
14
22
22
22
22
22
22
22
22
22
23
23
24
26
28
32
39
41
43
46
53
71
84
144
19
21
26
3
4
5
5
6
7
8
8
8
9
37
44
57
58
64
79
82
100
109
130
138
155
164
170
20
21
27
29
35
35
37
39
55
55
57
59
6
8
8
9
9
9
9
10
10
10
10
10
10
10
11
11
16
19
19
60
60
60
60
61
61
8
8
8
8
8
8
8
8
8
8
9
988888888886161606060601919161111101010101010109999886595755553937353529272120170164155138130109100827964585744379888765543262119144847153464341393228262423232222222222222222221414140000300300300300300300300200200000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-123
-161
-200
-240
-280
-240
-240
-701
-701
-701
0
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-602
-372
-451
-383
-1,036
-739
-492
-259
-54
-22
0
0
-8
-68
-55
100
1,583
2,779
4,297
4,290
5,002
4,152
4,156
4,174
4,149
0
0
0
0
-3,023
0
1
0
1
0
2
1
0
0
0
0
0
0
-58
-29
-28
-59
-31
-29
-32
-18
0
2
2
0
-7
-12
-13
-72
-17
-64
-70
-196
-70
-90
-29
-52
-50
-100
-42
-104
-77
-32
-81
-78
-78-81-32-77-104-42-100-50-52-29-90-70-196-70-64-17-72-13-12-70220-18-32-29-31-59-28-29-580000001201010-3,02300004,1494,1744,1564,1525,0024,2904,2972,7791,583100-55-68-800-22-54-259-492-739-1,036-383-451-372-602-602-602-602-602-602-602-602-602-602-602-602-602-602-602-6020-701-701-701-240-240-280-240-200-161-1230000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-200
400
600
600
600
600
600
600
500
2,900
3,400
3,400
7,400
8,914
8,807
8,829
9,514
8,834
8,835
8,837
8,838
8,838
9,539
8,839
9,450
9,466
9,501
9,545
9,835
9,949
10,374
11,101
11,139
11,243
11,413
11,754
12,969
14,895
15,979
19,815
20,950
23,908
24,626
33,506
34,802
35,881
37,626
39,440
40,850
41,049
50,591
52,613
96,608
106,329
129,486
132,974
141,138
166,301
174,599
192,576
200,859
211,636
215,185
225,529
230,553
235,448
248,212
259,517
298,889
309,671
340,664
342,603
349,723
360,798
393,884
394,309
395,840
397,716
397,992
409,568
409,664
413,349
429,899
432,299
432,336
432,430
434,630
435,520
435,725
437,142
437,425
437,680
438,203
438,622
448,594
457,852
458,040
543,893
544,185
544,893
545,336
545,872
546,268
573,358
573,840
574,429
575,465
575,766
576,263
576,575
576,844
577,170
577,710
578,215
578,215577,710577,170576,844576,575576,263575,766575,465574,429573,840573,358546,268545,872545,336544,893544,185543,893458,040457,852448,594438,622438,203437,680437,425437,142435,725435,520434,630432,430432,336432,299429,899413,349409,664409,568397,992397,716395,840394,309393,884360,798349,723342,603340,664309,671298,889259,517248,212235,448230,553225,529215,185211,636200,859192,576174,599166,301141,138132,974129,486106,32996,60852,61350,59141,04940,85039,44037,62635,88134,80233,50624,62623,90820,95019,81515,97914,89512,96911,75411,41311,24311,13911,10110,3749,9499,8359,5459,5019,4669,4508,8399,5398,8388,8388,8378,8358,8349,5148,8298,8078,9147,4003,4003,4002,900500600600600600600600400-200000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,000
Cost of Revenue-174
Gross Profit826826
 
Operating Income (+$)
Gross Profit826
Operating Expense-23,409
Operating Income-22,409-22,583
 
Operating Expense (+$)
Research Development11,334
Selling General Administrative12,075
Selling And Marketing Expenses0
Operating Expense23,40923,409
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-22,409
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,783-24,035
EBIT - interestExpense = -22,409
-20,783
-19,985
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-22,409-20,783
Earnings Before Interest and Taxes (EBITDA)-22,235
 
After tax Income (+$)
Income Before Tax-20,783
Tax Provision--798
Net Income From Continuing Ops-19,985-19,985
Net Income-19,985
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses23,409
Total Other Income/Expenses Net1,6260
 

Technical Analysis of Lisata
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lisata. The general trend of Lisata is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lisata's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Lisata Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lisata Therapeutics Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.26 < 2.335 < 2.3536.

The bearish price targets are: 2.07 > 2.07 > 1.87.

Know someone who trades $LSTA? Share this with them.πŸ‘‡

Lisata Therapeutics Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lisata Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lisata Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lisata Therapeutics Inc.. The current macd is -0.11077609.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lisata price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lisata. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lisata price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Lisata Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartLisata Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lisata Therapeutics Inc.. The current adx is 16.75.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lisata shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Lisata Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lisata Therapeutics Inc.. The current sar is 2.70040173.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lisata Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lisata Therapeutics Inc.. The current rsi is 37.48. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Lisata Therapeutics Inc. Daily Relative Strength Index (RSI) ChartLisata Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lisata Therapeutics Inc.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lisata price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Lisata Therapeutics Inc. Daily Stochastic Oscillator ChartLisata Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lisata Therapeutics Inc.. The current cci is -163.86494543.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Lisata Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartLisata Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lisata Therapeutics Inc.. The current cmo is -31.66714459.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lisata Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartLisata Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lisata Therapeutics Inc.. The current willr is -82.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Lisata Therapeutics Inc. Daily Williams %R ChartLisata Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Lisata Therapeutics Inc..

Lisata Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lisata Therapeutics Inc.. The current atr is 0.19048926.

Lisata Therapeutics Inc. Daily Average True Range (ATR) ChartLisata Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lisata Therapeutics Inc.. The current obv is 1,168,755.

Lisata Therapeutics Inc. Daily On-Balance Volume (OBV) ChartLisata Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lisata Therapeutics Inc.. The current mfi is 10.68.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Lisata Therapeutics Inc. Daily Money Flow Index (MFI) ChartLisata Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lisata Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Lisata Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lisata Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.485
Ma 20Greater thanMa 502.461
Ma 50Greater thanMa 1002.595
Ma 100Greater thanMa 2002.521
OpenGreater thanClose2.080
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lisata with someone you think should read this too:
  • Are you bullish or bearish on Lisata? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lisata? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lisata Therapeutics Inc.

I send you an email if I find something interesting about Lisata Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Lisata Therapeutics Inc..

Receive notifications about Lisata Therapeutics Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.